Last reviewed · How we verify
approved influenza vaccine
At a glance
| Generic name | approved influenza vaccine |
|---|---|
| Sponsor | Changchun BCHT Biotechnology Co. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (PHASE1)
- A/Texas Flu Challenge (PHASE1)
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults (PHASE4)
- Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza (PHASE3)
- A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant) (PHASE1)
- Systems Biological Assessment of Statin Effect on Vaccine Responses (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- approved influenza vaccine CI brief — competitive landscape report
- approved influenza vaccine updates RSS · CI watch RSS
- Changchun BCHT Biotechnology Co. portfolio CI